Summary
The massive, early and relatively circumscribed death of the dopaminergic neurons of the substantia nigra in Parkinson’s disease has not yet been adequately explained. The characteristic feature of this brain region is the presence of neuromelanin pigment within the vulnerable neurons. We suggest that neuromelanin in the Parkinson’s disease brain differs to that in the normal brain. The interaction of neuromelanin with iron has been shown to differ in the parkinsonian brain in a manner consistent with an increase in oxidative stress. Further, we suggest an interaction between the lipoprotein α-synuclein and lipidated neuromelanin contributes to the aggregation of this protein and cell death in Parkinson’s disease. The available data suggest that the melaninisation of the dopaminergic neurons of the substantia nigra is a critical factor to explain the vulnerability of this brain region to early and massive degeneration in Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aime S, Bergamasco, B, Casu M, Digilio G, Fasano M, Giraudo S, Lopiano L (2000) Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson’s disease. Mov Disord 15: 977–981
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24: 197–211
Double K, Riederer P, Gerlach M (1999) The significance of neuromelanin in Parkinson’s disease. Drug News Dev 12: 333–340
Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MBH, Riederer P, Ben-Shachar D (2003) Iron binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66: 489–494
Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L (2003) Residual substantia nigra neuromelanin in Parkinson’s disease is cross-linked to alpha-synuclein. Neurochem Int 42: 603–606
Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem 86: 1142–1148
Fedorow H, Pickford R, Hook JM, Double KL, Halliday G, Gerlach M, Riederer P, Garner B (2005) Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem 92:990–995
Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL (2005) Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson’s disease. Prog Neurobiol 75: 109–124
Gerlach M, Trautwein AX, Zecca L, Youdim MBH, Riederer P (1995) Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem 65: 923–926
Götz M, Double KL, Gerlach M, Youdim MBH, Riederer P (2004) The relevance of iron in the pathogenesis of Parkinson’s disease. Ann NY Acad Sci 1012: 193–208
Hirsch E, Graybiel A, Agid Y (1988) Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 28:345–348
Huang Y, Cheung L, Rowe D, Halliday G (2004) Genetic contributions to Parkinson’s disease. Brain Res Rev 46: 44–70
Kastner A, Hirsch E, Lejeune O, Javoy-Agid F, Rascol F, Agid Y (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? J Neurochem 59: 1080–1089
Kaur D, Andersen J (2004) Does cellular iron dysregulation play a causative role in Parkinson’s disease? Ageing Res Rev 3: 327–343
Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, Halliday G, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL (2005) Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 95: 599–608
Lopiano L, Chiesa M, Digilio D, Giraudo G, Bergamasco B, Fasano M (2000) Q-band EPR investigations of neuromelanin in control and Parkinson’s disease patients. Biochem Biophys Acta 1500: 306–312
McRitchie DA, Cartwright H, Halliday GM (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp Neurol 144:202–213
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag
About this paper
Cite this paper
Double, K.L., Halliday, G.M. (2006). New face of neuromelanin. In: Riederer, P., Reichmann, H., Youdim, M.B.H., Gerlach, M. (eds) Parkinson’s Disease and Related Disorders. Journal of Neural Transmission. Supplementa, vol 70. Springer, Vienna . https://doi.org/10.1007/978-3-211-45295-0_19
Download citation
DOI: https://doi.org/10.1007/978-3-211-45295-0_19
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-28927-3
Online ISBN: 978-3-211-45295-0
eBook Packages: MedicineMedicine (R0)